At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 306 enrolled
Drug / intervention
Enapotamab vedotin (HuMax-AXL-ADC)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Enapotamab vedotin (HuMax-AXL-ADC) for Ovarian Cancer and 7 related conditions. Completed, enrolled 306 participants across 41 sites in 6 countries.
Detailed Summary
The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Cervical Cancer, Endometrial Cancer, Non Small Cell Lung Cancer (NSCLC), Thyroid Cancer, Melanoma, Sarcoma, Solid Tumors
CountriesBelgium, Denmark, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedDec 2016
Primary CompletionNov 2021
TodayJul 2026
First PostedDec 9, 2016
Enrollment StartNov 23, 2016
Primary CompletionNov 12, 2021
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.6 years ago
Interventions
Enapotamab vedotin (HuMax-AXL-ADC)biological
Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.